Carvedilol
- Generic Name
- Carvedilol
- Brand Names
- Coreg
- Drug Type
- Small Molecule
- Chemical Formula
- C24H26N2O4
- CAS Number
- 72956-09-3
- Unique Ingredient Identifier
- 0K47UL67F2
- Background
Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker. It is currently used to treat heart failure, left ventricular dysfunction, and hypertension. The dual action of carvedilol is advantageous in combination therapies as moderate doses of 2 drugs have a decreased incidence of adverse effects compared to high dose monotherapy in the treatment of moderate hypertension.
Carvedilol was granted FDA approval on 14 September 1995.
- Indication
Carvedilol is indicated to treat mild to severe heart failure, left ventricular dysfunction after myocardial infarction with ventricular ejection fraction ≤40%, or hypertension.
- Associated Conditions
- Atrial Fibrillation, Chronic Stable Angina Pectoris, Hypertension, LVEF ≤40% Left ventricular dysfunction, NYHA Class I or II heart failure, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV)
Cytochrome P450 2D6 Genotype on the Clinical Effect of Carvedilol
- First Posted Date
- 2014-11-10
- Last Posted Date
- 2015-06-04
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 24
- Registration Number
- NCT02286934
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Gyounggi, Korea, Republic of
Rate Control in Atrial Fibrillation
- First Posted Date
- 2014-09-29
- Last Posted Date
- 2016-06-16
- Lead Sponsor
- Creighton University
- Target Recruit Count
- 20
- Registration Number
- NCT02251509
- Locations
- 🇺🇸
Creighton University, Omaha, Nebraska, United States
Biomarker Guided Therapies in Stage A/B Heart Failure
- Conditions
- DiabetesCardiovascular DiseaseHypertension
- Interventions
- First Posted Date
- 2014-09-03
- Last Posted Date
- 2022-10-21
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 58
- Registration Number
- NCT02230891
- Locations
- 🇺🇸
Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States
Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 82
- Registration Number
- NCT02177175
- Locations
- 🇺🇸
Memorial Sloan Kettering West Harrison, Harrison, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
The Cardiac Insufficiency BIsoprolol Study in Japanese Patients With Chronic Heart Failure (CIBIS-J)
- First Posted Date
- 2014-05-14
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- Mebix Inc
- Target Recruit Count
- 220
- Registration Number
- NCT02137733
- Locations
- 🇯🇵
Chukyo Hospital, Nagoya, Aichi, Japan
🇯🇵Takezawa Clinic, Nagoya, Aichi, Japan
🇯🇵St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
Carvedilol PAH A Pilot Study of Efficacy and Safety
- First Posted Date
- 2014-04-22
- Last Posted Date
- 2019-07-12
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 5
- Registration Number
- NCT02120339
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
Carvedilol vs Band Ligation vs Combination Therapy for Primary Prophylaxis of Variceal Bleeding
- Conditions
- Portal Hypertension Related to Cirrhosis
- Interventions
- Procedure: Variceal band ligation
- First Posted Date
- 2014-02-19
- Last Posted Date
- 2018-07-24
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Registration Number
- NCT02066649
- Locations
- 🇺🇸
Rutgers NJ Medical School, Newark, New Jersey, United States
Conditioned Pharmacotherapeutic Effects in Hypertension
- First Posted Date
- 2014-02-06
- Last Posted Date
- 2019-07-09
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 44
- Registration Number
- NCT02056626
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
A Phase Ⅲ Study of Extended-Release Carvedilol Sulfate for the Treatment of Heart Failure
- Conditions
- Heart Failure
- Interventions
- First Posted Date
- 2013-12-16
- Last Posted Date
- 2013-12-16
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 316
- Registration Number
- NCT02012075
- Locations
- 🇨🇳
Gansu Provincial Hospital, Lanzhou, Gansu, China
🇨🇳Tongji Hospital, Wuhan, Hubei, China
🇨🇳The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
A Phase Ⅲ Study of Extended-Release Carvedilol Sulfate for the Treatment of Hypertension
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2013-10-25
- Last Posted Date
- 2013-10-25
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 302
- Registration Number
- NCT01970059
- Locations
- 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China
🇨🇳Beijing Tongren hospital affiliated to Capital Medical University, Beijing, China
🇨🇳Gansu Provincial Hospital, Lanzhou, Gansu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.